Put companies on watchlist
Aerovate Therapeutics
ISIN: US0080641071
WKN: A3CTMQ
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

Aerovate Therapeutics · ISIN: US0080641071 · Business Wire (ID: 20241031475491)
31 October 2024 02:31PM

Shareholder Alert: Ademi LLP Investigates Whether Aerovate Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders


Ademi LLP is investigating Aerovate (Nasdaq: AVTE) for possible breaches of fiduciary duty and other violations of law in its transaction with Jade.

Click here to learn how to join our investigation or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.

Under the agreement, Aerovate stockholders are expected to own approximately 1.6% of the combined company, while Jade stockholders — including those investors participating in the pre-closing financing — are expected to own approximately 98.4%. Aerovate will also pay a dividend of approximately $65 million to Aerovate stockholders immediately prior to the closing of the merger.

The transaction agreement unreasonably limits competing transactions for Aerovate by imposing a significant penalty if Aerovate accepts a competing bid. Aerovate insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Aerovate’s board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

If you own Aerovate common stock and wish to obtain additional information, please contact Guri Ademi either at gademi@ademilaw.com or toll-free: 866-264-3995, or here.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

Visual performance / price development - Aerovate Therapeutics
Smart analysis and research tools can be found here.
This publication was provided by our content partner Business Wire
BusinessWire
via BusinessWire - Newsfeed
BusinessWire ©2025
BusinessWire
Contact:
101 California Street, 20th Floor San Francisco, CA, 94111 United States
+1.415.986.4422